8-K

                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15 (d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

       Date of Report (Date of earliest event reported): January 26, 2006
                            POINT THERAPEUTICS, INC.
               (Exact Name of Registrant as Specified in Charter)

                       DELAWARE                 0-19410
              (State or Other Jurisdiction (Commission File Number)
                      of Incorporation)

                 155 FEDERAL STREET, BOSTON, MASSACHUSETTS 02110
                    (Address of Principal Executive Offices)

       Registrant's telephone number, including area code: (617) 933-2130

                                       N/A

          (Former Name or Former Address, if Changed Since Last Report)





Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act
    (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))



Item 8.01         Other Events

                  Point Therapeutics, Inc. ("Point") issued a press release on
                  January 26, 2006 announcing that it changed the start time for
                  its live webcast on Tuesday, January 31 to 8:30 AM EST.


                  A copy of the press release dated January 26, 2006 is being
                  filed as Exhibit 99.1 to this Current Report on Form 8-K.



Item 9.01         Financial Statements and Exhibits.

                  (c) Exhibits.

                  99.1 - Press release issued by Point dated January 26, 2006.



                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                  POINT THERAPEUTICS, INC.


January 27, 2006                  By:  /s/ Donald R. Kiepert, Jr.
                                      -------------------------
                                Name: Donald R. Kiepert, Jr.
                               Title: President, Chief Executive Officer




                                  EXHIBIT INDEX

The following exhibit is filed herewith:

Exhibit     Description
- -------     -----------
99.1        Press release issued by Point Therapeutics, Inc. ("Point") on
            January 26, 2006 announcing that it changed the start time for
            its live webcast on Tuesday, January 31 to 8:30 AM EST.

EX-99.1

                                                                    Exhibit 99.1

Point Therapeutics Announces Time Change for January 31, 2006 Webcast; Webcast
on Phase 3 NSCLC Program and Clinical Update Moved to 8:30 AM EST

    BOSTON--(BUSINESS WIRE)--Jan. 26, 2006--Point Therapeutics, Inc.
(NASDAQ:POTP) announced today that it has changed the start time for
its live webcast on Tuesday, January 31 to 8:30 AM EST.
    The webcast may be accessed by visiting www.pther.com.

    About Point Therapeutics, Inc.:

    Point is developing a family of dipeptidyl peptidase (DPP)
inhibitors for use in cancer, type 2 diabetes and as vaccine
adjuvants. The Company is currently studying its lead product
candidate, talabostat, in a Phase 3 trial in metastatic NSCLC.
Additionally, talabostat is being evaluated in several Phase 2 trials;
including, as a single-agent in metastatic melanoma, in combination
with cisplatin in metastatic melanoma, in combination with rituximab
in advanced chronic lymphocytic leukemia, and in combination with
gemcitabine in metastatic pancreatic cancer. Point's portfolio also
includes two other DPP inhibitors in preclinical development--PT-630
for type 2 diabetes, and PT-510 as a vaccine adjuvant.

    Certain statements contained herein are not strictly historical
and are "forward looking" statements as defined in the Private
Securities Litigation Reform Act of 1995. This information includes
statements with respect to the company's clinical development
programs, the timing of initiation and completion of its clinical
trials, and the potential of talabostat to become an important
treatment for chronic lymphocytic leukemia cancer. Forward-looking
statements are statements that are not historical facts, and can be
identified by, among other things, the use of forward-looking
language, such as "believes," "feels," "expects," "may," "will,"
"should," "seeks," "plans," "schedule to," "anticipates" or "intends"
or the negative of those terms, or other variations of those terms of
comparable language, or by discussions of strategy or intentions. A
number of important factors could cause actual results to differ
materially from those projected or suggested in the forward looking
statement, including the risk factors described in Point's quarterly
report on Form 10-Q for the quarter ended September 30, 2005 and from
time to time in Point's periodic and other reports filed with the
Securities and Exchange Commission.

    CONTACT: Point Therapeutics, Inc.
             Sarah Cavanaugh, 617-933-7508
             Director, Corporate Communications